TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14365/4

Browse

Filters

20222

Settings

Author: search.filters.author.Türk, Uğur ÖnselHas files: Yes

Search Results

Now showing 1 - 2 of 2
  • Article
    Citation - WoS: 8
    Citation - Scopus: 7
    Evaluation of Demographic and Clinical Characteristics of Female Patients Presenting With Minoca and Differences Between Male Patients: a Subgroup Analysis of Minoca-Tr Registry
    (Kare Publ, 2022-01-06) Gok, Gulay; Coner, Ali; Cinar, Tufan; Kilic, Salih; Yenercag, Mustafa; Oz, Ahmet; Ekmekci, Cenk; Türk, Uğur Önsel; Zoghi, Mehdi; Ergene, Asim Oktay
    Objective: Although the prevalence and rate of myocardial infarction with non-obstructive coronary arteries (MINOCA) are higher in women than in men in previous cohorts, potential demographic and clinical differences between women who are diagnosed with MINOCA versus myocardial infarction with obstructive coronary arteries (MIOCA) have not been studied till date. In this study, we aimed to document these characteristics and to compare them between female patients with MINOCA and MIOCA. Methods: The study was a subgroup analysis of the MINO-CA-TR study. The study was a multi-center, observational cohort study that was conducted in Turkey between March 2018 and October 2018. In this study, 477 (29.3%) female patients who had been diagnosed with acute myocardial infarction were evaluated. Results: Of these women, 49 (10.3%) were diagnosed with MINOCA (mean age 58.9 +/- 12.9 years) and 428 (89.7%) had a final diagnosis of MIOCA (mean age 67.4 +/- 11.8 years). The prevalence of hypertension, hyperlipidemia, and diabetes mellitus was significantly lower in the MINOCA group than in the MIOCA group. In addition, the MINOCA group had higher rates of recent flu history and non-ST elevation myocardial infarction (NSTEMI) presentation than the MIOCA group. There were significant clinical differences in patients with MINOCA in terms of sex. The female patients were older, had higher systolic blood pressures, and lower hemoglobin levels than male patients. Conclusion: The study revealed that the prevalence of traditional coronary artery disease risk factors was lower in female patients with MINOCA than in those who had final diagnosis of MIOCA.
  • Article
    Citation - WoS: 1
    Citation - Scopus: 2
    Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale
    (Aves, 2022-03-16) Türk Uğur Önsel; Alioglu, Emin; Mavioglu, Zafer; Diker, Erdem; Ozpelit, Ebru; De Caterina, Raffaele; Türk, Uğur Önsel; Caterina, Raffaele De
    Objective: Safety and effectiveness of edoxaban was demonstrated in phase III, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF-TIMI 48) trial and is being confirmed in the post-authorization Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study in patients with atrial fibrillation. However. any post-authorization safety study focusing on the safety of edoxaban treatment in Turkey with a prospective design has not been performed yet. The Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR) study is designed to evaluate the safety and effectiveness of edoxaban treatment in atrial fibrillation in routine practice. The present article describes the design and rationale for the ETAF-TR Study. Methods: The ETAF-TR (NCT04594915) is a national. multicenter. prospective, observational study that enrolled 858 patients from 32 centers. The primary outcome of the ETAF-TR study is any overt bleeding (consisting of major bleeding or clinically relevant nonmajor bleeding or any bleeding that does not meet this definition but is considered as overt bleeding by the participating physician). Effectiveness, treatment persistence. and posology will also be evaluated in an explorative manner. The overall duration of follow-up will be 1 year: the first patient was enrolled in August 2020. Conclusions: Results of ETAF-TR wilt add data from clinical practice to those from ENGAGE-AF trial and also ETNA-AF study. Comparing their results will enable to test the external validity of ENGAGE-AF trial in the country conditions.